Back to Search
Start Over
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
- Source :
-
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2024 Feb; Vol. 29 (7). - Publication Year :
- 2024
-
Abstract
- The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).
Details
- Language :
- English
- ISSN :
- 1560-7917
- Volume :
- 29
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
- Publication Type :
- Academic Journal
- Accession number :
- 38362622
- Full Text :
- https://doi.org/10.2807/1560-7917.ES.2024.29.7.2400076